⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IOVA News
Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
globenewswire.com
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Tumor Microenvironment Modulation Market to Hit USD 3.73 Billion by 2031 with a 7.4% CAGR - Key Trends and Insights
globenewswire.com
BMY
MRK
AZN
PFE
REGN
GILD
AMGN
BE
LLY
IOVA
NVS
Form 8-K
sec.gov
IOVA
Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
prnewswire.com
PFE
ABBV
RMD
GSK
AZN
BNTX
INCY
IOVA
RGEN
MRK
LLY
IBIO
GILD
AMGN
JNJ
NVS
RIGL
BIIB
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
IOVA
Form 8-K
sec.gov
IOVA
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
globenewswire.com
IOVA
GTBP
NKTX
IBRX
FATE
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
globenewswire.com
IOVA